Literature DB >> 26700059

Comparison of long-term patency after endovascular therapy for superficial femoral artery occlusive disease between patients with and without hemodialysis.

Junya Matsumi1, Kazuki Tobita1, Koki Shishido1, Shingo Mizuno1, Futoshi Yamanaka1, Masato Murakami1, Yutaka Tanaka1, Saeko Takahashi1, Takeshi Akasaka1, Shigeru Saito1.   

Abstract

OBJECTIVE: To compare long-term patency after endovascular therapy (EVT) for superficial femoral artery (SFA) occlusive disease between patients with hemodialysis (HD; HD+) and those without HD (HD-).
BACKGROUND: Long-term patency after EVT for SFA occlusive disease in HD+ remains unknown.
METHODS: EVT to SFA was successfully performed in 382 consecutive patients during 2004-2011. Cox proportional hazard model estimated the hazard ratio (HR) for the loss of primary patency (PP), secondary patency (SP), and amputation-free survival (AFS) in HD+. Binominal logistic regression analysis calculated the propensity score (PS) for covariates with a P value of <0.2 for HD as a dependent variable. HRs were adjusted for PS in multivariate analysis using the Cox proportional hazard model.
RESULTS: PP and SP in HD+ and HD- were 47.9 and 79.4% and 68.4 and 92.5%, respectively, 4 years after EVT. There were no procedure-related amputations or in-hospital deaths. Adjusted HRs for the loss of PP, SP, and AFS were as follows: loss of PP, adjusted HR 2.010, 95% CI 1.157-3.492, P = 0.013; loss of SP, adjusted HR 2.927, 95% CI 1.236-6.933, P = 0.015; and loss of AFS, adjusted HR 1.665, 95% CI 0.994-2.791, P = 0.053.
CONCLUSIONS: Although HD+ had more than double the risks for loss of PP and SP than HD-, EVT to SFA in HD+ was found to be safe with an acceptable PP and SP.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  endovascular therapy; hemodialysis; superficial femoral artery

Mesh:

Year:  2015        PMID: 26700059     DOI: 10.1002/ccd.26359

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  2 in total

Review 1.  Current Perspective on Hemodialysis Patients with Peripheral Artery Disease.

Authors:  Shin Okamoto; Osamu Iida; Toshiaki Mano
Journal:  Ann Vasc Dis       Date:  2017-06-25

2.  Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.

Authors:  Yukihisa Ogawa; Hiroyoshi Yokoi; Takao Ohki; Kimihiko Kichikawa; Masato Nakamura; Kimihiro Komori; Shinsuke Nanto; Erin E O'Leary; Aaron E Lottes; Alan T Saunders; Michael D Dake
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-09       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.